Lantern Pharma Inc.
LTRN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $175 | $0 | $0 |
| Gross Profit | $0 | -$175 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $16,126 | $11,894 | $8,603 | $7,571 |
| G&A Expenses | $6,091 | $5,983 | $5,830 | $5,021 |
| SG&A Expenses | $6,091 | $5,983 | $5,830 | $5,021 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$175 | $0 | $0 |
| Operating Expenses | $22,216 | $17,703 | $14,433 | $12,592 |
| Operating Income | -$22,216 | -$17,878 | -$14,433 | -$12,592 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,435 | $1,916 | $173 | $228 |
| Pre-Tax Income | -$20,781 | -$15,962 | -$14,260 | -$12,363 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$20,781 | -$15,962 | -$14,260 | -$12,363 |
| % Margin | – | – | – | – |
| EPS | -1,930.92 | -1.47 | -1.31 | -1.13 |
| % Growth | -131,255.1% | -12.2% | -15.9% | – |
| EPS Diluted | -1,930.92 | -1.47 | -1.31 | -1.13 |
| Weighted Avg Shares Out | 10,762 | 10,842 | 10,851 | 10,905 |
| Weighted Avg Shares Out Dil | 10,762 | 10,842 | 10,851 | 10,905 |
| Supplemental Information | – | – | – | – |
| Interest Income | $742 | $765 | $204 | $68 |
| Interest Expense | $0 | $0 | $204 | $0 |
| Depreciation & Amortization | $17 | $175 | $10 | $7 |
| EBITDA | -$22,199 | -$15,787 | -$14,423 | -$12,585 |
| % Margin | – | – | – | – |